Emerging disease-modifying therapies for sickle cell disease

Area of Science:

• Hematology
• Genetics
• Pharmacology

Background:

• Sickle cell disease (SCD) affects millions globally, causing severe complications like anemia, vaso-occlusion, and organ damage.
• Current FDA-approved treatments for SCD are limited, with only hydroxyurea and L-glutamine widely available.
• Despite SCD's prevalence, drug development has lagged compared to other genetic disorders like cystic fibrosis.

Purpose of the Study:

• To review disease-modifying therapeutic strategies for sickle cell disease currently in clinical trials.
• To focus on approaches developed in the era following hydroxyurea's approval.
• To exclude hematopoietic stem cell transplantation and gene therapy from the review.

Main Methods:

• Review of clinical trial data for novel SCD therapeutics.
• Identification of therapeutic strategies targeting SCD pathophysiology.
• Analysis of drug development trends in SCD management.

Main Results:

• Multiple novel drug candidates are in clinical trials for sickle cell disease.
• Therapeutic strategies include fetal hemoglobin induction, HbS polymerization inhibition, and anti-inflammatory approaches.
• New agents aim to prevent SCD complications and improve patient outcomes.

Conclusions:

• The landscape of sickle cell disease treatment is evolving with new investigational therapies.
• Multimodal agent therapy is emerging as a key strategy to combat SCD.
• Recent clinical trials show promise for novel disease-modifying approaches in SCD management.